fluorodeoxyglucose f18 has been researched along with Lymphangiomyomatosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corbridge, TC; Fletcher, CDM; Franz, DN; Galsky, MD; Gelfand, MJ; Lam, AP; McCormack, FX; Nagarkatte, P; Wikenheiser-Brokamp, KA; Young, LR | 1 |
| Pandit, N; Yeung, HW | 1 |
2 other study(ies) available for fluorodeoxyglucose f18 and Lymphangiomyomatosis
| Article | Year |
|---|---|
Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Lymphangioleiomyomatosis; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Tuberous Sclerosis | 2009 |
F-18 FDG uptake in pulmonary lymphangioleiomyomatosis.
Topics: Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphangioleiomyomatosis; Middle Aged; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |